Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Small molecule probe for IBD risk variant GPR65 I231L alters cytokine signaling networks through positive allosteric modulation

ABSTRACT: Small molecule probe for IBD risk variant GPR65 I231L alters cytokine signaling networks through positive allosteric modulation

PROVIDER: PRJNA1019398 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26128700_1.fastq.gz	Fastqsanger.gz
	SRR26128700_2.fastq.gz	Fastqsanger.gz
	SRR26128701_1.fastq.gz	Fastqsanger.gz
	SRR26128701_2.fastq.gz	Fastqsanger.gz
	SRR26128702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 180

Similar Datasets

Small molecule probe for IBD risk variant GPR65 I231L alters cytokine signaling networks through positive allosteric modulation

Project description:BRD5075 is a positive allosteric modulator of GPR65. Activity has been demonstrated by cAMP production in HeLa cells overexpessing GPR65 and target engagment has been confirmed. BRD5075 also decreases TNF-a secretion by GPR65 WT BMDCs. Goal is to identify differentially expressed genes in response to this GPR65 PAM

2024-06-27 | GSE243692 | GEO

Crohn's disease risk variant in GPR65 alters lysosomal function

Project description:Using an siRNA screen we identify a role for GPR65 in the defense against intracellular pathogens. Epithelial cells and macrophages lacking GPR65 exhibited impaired clearance of intracellular bacteria as well as an accumulation of aberrant phagosomes and lysosomes. Transcriptional profiling revealed changes in genes associated with lysosomal function. Bone marrow-derived macrophages from WT or Gpr65-/- mice were harvested for RNA analysis.

2016-06-15 | E-GEOD-69445 | biostudies-arrayexpress

Crohn's disease risk variant in GPR65 alters lysosomal function

2016-06-15 | GSE69445 | GEO

Small Molecule Allosteric inhibitors of GPX4

Project description:Encouraged by the dependence of drug-resistant, metastatic cancers on GPX4, we examined biophysical mechanisms of GPX4 inhibition, which revealed an unexpected allosteric binding site. We found that this site was involved in native modulation of GPX4 activity. Binding of inhibitors to this allosteric site caused a conformational change, inhibition of activity, and subsequent cellular GPX4 protein degradation. To verify this binding site in an unbiased manner, we screened a library of compounds, and identified and validated that a novel additional compound can bind in this allosteric site, inhibiting and degrading GPX4. We determined co-crystal structures of six different inhibitors bound in this site. We have thus discovered a new allosteric mechanism for small molecules targeting aggressive cancers dependent on GPX4.

2022-10-12 | MSV000090526 | MassIVE

Expression data that were specifically regulated by GPR65 in livers of mice undergoing BDL-induced liver fibrosis

Project description:GPCRs are the most productive drug targets and targeted by one third of the drugs in clinical use, however, few GPCRs are reported to participate in liver fibrosis. In this study, we have identified that KCs-enriched GPR65 is upregulated in both human and mouse fibrotic livers and KCs from fibrotic livers. To identify the roles of GPR65 in liver fibrosis, we performed RNA-seq to analyze the effect of Gpr65 deficiency on BDL-induced liver fibrosis. The mice were divided into four groups: sham operation- treated WT mice (n=3), bile duct ligation (BDL)- treated WT mice (n=3), sham operation- treated GPR65-KO mice (n=3) and BDL- treated GPR65-KO mice (n=3).

2023-11-18 | GSE182235 | GEO

The allosteric landscape of the Src kinase

Project description:Enzymes catalyze the reactions of life and are the targets of nearly all small molecule drugs. Most drugs inhibit enzymes by binding to conserved active sites, causing problems of specificity and toxicity. Targeting regulatory allosteric sites can increase specificity, overcome drug resistance and tune or activate activity.However, the vast majority of enzymes have no known allosteric sites and methods do not exist to globally identify or predict them.Here we present a general and fast method to globally chart allosteric communication in enzymes and apply it to the Src protein kinase to produce the first comprehensive map of negative and positive allosteric control of enzymatic activity. Allosteric control of Src is pervasive, anisotropic and distance dependent, but fairly predictable from simple sequence and structural features. The comprehensive allosteric map enables unbiased identification of all the allosterically active surface pockets of the Src kinase for the development of activatory and inhibitory drugs.This general approach can be used to chart global allosteric maps of many kinases, enzymes, and other biochemical activities important for medicine and biotechnology.

2024-04-27 | GSE247740 | GEO

microRNA-seq in circCDYL probe and NC probe

Project description:microRNA-seq in circCDYL probe and NC probe

| PRJNA730505 | ENA

B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [scRNA-Seq]

Project description:Chimeric antigen receptor (CAR)-T cell therapy has shown promise in treating CD19+ hematological tumors, but some patients fail to respond. Here we used an immune-competent mouse model of B cell acute lymphoblastic leukemia (B-ALL) to assess clonal tumor populations with distinct responses to CAR-T cell therapy. We identified GPR65 as a determinant of tumor responsiveness to CAR-T cell therapy, with high GPR65 expression associated with a complete response. GPR65 KO tumors were resistant to CAR-T treatment in vivo. This was associated with increased tumor VEGFA expression driven by FOXO1 activation and expanded host macrophages. Either depletion of host macrophages or deletion of VEGFA from GPR65 KO tumors restored responsiveness to CAR-T cell treatment. Anti-VEGFa therapy, in combination with CD19-CAR-T, prolongs the survival of GPR65-KO tumor-bearing mice in pre-clinical models. Our results indicate that GPR65 may be a useful biomarker for tumor responsiveness to CAR-T cell therapy and further suggest VEGFA or host macrophages as therapeutic targets to improve CAR-T efficacy.

2025-01-30 | GSE236031 | GEO

B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [RNA-Seq]

2025-01-30 | GSE266240 | GEO

B-ALL GPR65 expression influences susceptibility to CAR-T therapy through a VEGF and macrophage-dependent mechanism [enrichement scRNA-Seq]

2025-01-30 | GSE266165 | GEO